Free Trial

Wave Life Sciences (WVE) Competitors

Wave Life Sciences logo
$6.09 +0.05 (+0.83%)
Closing price 04:00 PM Eastern
Extended Trading
$6.42 +0.33 (+5.40%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

WVE vs. KRYS, CYTK, RYTM, PTCT, SRPT, RNA, SWTX, RARE, AKRO, and ACLX

Should you be buying Wave Life Sciences stock or one of its competitors? The main competitors of Wave Life Sciences include Krystal Biotech (KRYS), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), Sarepta Therapeutics (SRPT), Avidity Biosciences (RNA), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), and Arcellx (ACLX). These companies are all part of the "pharmaceutical products" industry.

Wave Life Sciences vs.

Krystal Biotech (NASDAQ:KRYS) and Wave Life Sciences (NASDAQ:WVE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, community ranking, risk, media sentiment, profitability and institutional ownership.

Krystal Biotech presently has a consensus price target of $211.13, suggesting a potential upside of 68.51%. Wave Life Sciences has a consensus price target of $21.17, suggesting a potential upside of 247.56%. Given Wave Life Sciences' higher probable upside, analysts plainly believe Wave Life Sciences is more favorable than Krystal Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Krystal Biotech
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.00
Wave Life Sciences
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
3.00

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 89.7% of Wave Life Sciences shares are held by institutional investors. 13.7% of Krystal Biotech shares are held by insiders. Comparatively, 29.1% of Wave Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Krystal Biotech has a net margin of 30.69% compared to Wave Life Sciences' net margin of -66.50%. Krystal Biotech's return on equity of 11.41% beat Wave Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Krystal Biotech30.69% 11.41% 10.40%
Wave Life Sciences -66.50%-280.57%-52.90%

Wave Life Sciences received 69 more outperform votes than Krystal Biotech when rated by MarketBeat users. However, 67.80% of users gave Krystal Biotech an outperform vote while only 67.77% of users gave Wave Life Sciences an outperform vote.

CompanyUnderperformOutperform
Krystal BiotechOutperform Votes
299
67.80%
Underperform Votes
142
32.20%
Wave Life SciencesOutperform Votes
368
67.77%
Underperform Votes
175
32.23%

In the previous week, Wave Life Sciences had 1 more articles in the media than Krystal Biotech. MarketBeat recorded 11 mentions for Wave Life Sciences and 10 mentions for Krystal Biotech. Wave Life Sciences' average media sentiment score of 1.30 beat Krystal Biotech's score of 1.20 indicating that Wave Life Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Krystal Biotech
7 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Wave Life Sciences
8 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Krystal Biotech has higher revenue and earnings than Wave Life Sciences. Wave Life Sciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Krystal Biotech$333.45M10.86$10.93M$4.1630.12
Wave Life Sciences$104.94M8.94-$57.51M-$0.84-7.25

Krystal Biotech has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -0.92, indicating that its share price is 192% less volatile than the S&P 500.

Summary

Krystal Biotech beats Wave Life Sciences on 10 of the 17 factors compared between the two stocks.

Get Wave Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

WVE vs. The Competition

MetricWave Life SciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$930.97M$6.48B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-5.499.0626.7119.71
Price / Sales8.94251.50386.13120.55
Price / CashN/A65.8538.2534.62
Price / Book15.236.456.774.50
Net Income-$57.51M$143.98M$3.23B$248.22M
7 Day Performance-3.33%2.41%1.80%0.56%
1 Month Performance-7.16%4.56%11.10%13.17%
1 Year Performance-5.43%-2.67%17.11%7.30%

Wave Life Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
WVE
Wave Life Sciences
4.3806 of 5 stars
$6.09
+0.8%
$21.17
+247.6%
-4.4%$930.97M$104.94M-5.49240Positive News
KRYS
Krystal Biotech
4.9093 of 5 stars
$139.43
+5.5%
$218.63
+56.8%
-24.1%$4.03B$333.45M46.63210Positive News
CYTK
Cytokinetics
4.1531 of 5 stars
$32.13
+1.4%
$74.44
+131.7%
-47.9%$3.84B$19.22M-5.97250
RYTM
Rhythm Pharmaceuticals
3.9428 of 5 stars
$58.97
+2.8%
$75.38
+27.8%
+64.2%$3.75B$130.13M-13.62140Positive News
PTCT
PTC Therapeutics
4.1848 of 5 stars
$46.01
+4.0%
$61.92
+34.6%
+18.9%$3.65B$1.77B-7.751,410Gap Up
SRPT
Sarepta Therapeutics
4.8153 of 5 stars
$36.37
+0.3%
$131.22
+260.8%
-69.0%$3.57B$2.23B29.10840Positive News
Analyst Forecast
High Trading Volume
RNA
Avidity Biosciences
1.9199 of 5 stars
$29.33
+5.2%
$66.38
+126.3%
+3.8%$3.53B$10.90M-10.18190Options Volume
SWTX
SpringWorks Therapeutics
2.3665 of 5 stars
$46.12
-0.3%
$52.57
+14.0%
+7.5%$3.46B$191.59M-13.25230Positive News
High Trading Volume
RARE
Ultragenyx Pharmaceutical
3.9707 of 5 stars
$36.09
+2.8%
$90.93
+152.0%
-12.7%$3.39B$560.23M-5.691,310Positive News
AKRO
Akero Therapeutics
3.8137 of 5 stars
$41.53
+4.2%
$76.29
+83.7%
+138.9%$3.31BN/A-11.0730Insider Trade
High Trading Volume
ACLX
Arcellx
1.6399 of 5 stars
$59.50
+3.4%
$109.31
+83.7%
+23.0%$3.28B$76.81M-83.8080

Related Companies and Tools


This page (NASDAQ:WVE) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners